The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press12610.17650/1818-8338-2011-2-80-85PHARMACOTHERAPYФАРМАКОТЕРАПИЯCLINICAL EFFECTIVENESS AND SAFETY OF IVABRADINE USE IN PATIENTS WITH UNSTABLE ANGINA AND DIABETES MELLITUS TYPE 2КЛИНИЧЕСКАЯ ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ИСПОЛЬЗОВАНИЯ ИВАБРАДИНА У ПАЦИЕНТОВ С НЕСТАБИЛЬНОЙ СТЕНОКАРДИЕЙ И САХАРНЫМ ДИАБЕТОМ 2-ГО ТИПАKondratievA. I.КондратьевА. И.
Russian Federation
rekio@bsmp1.omsk.ruOmsk State Medical Academy, Ministry of Health and Social Development of Russia Municipal City Hospital of Emergency Medical Care № 1, OmskГОУ ВПО Омская государственная медицинская академия Минздравсоцразвития России МУЗ Городская клиническая больница скорой медицинской помощи № 1, Омск150420115280851707201417072014Copyright ©; 2011, Kondratiev A.I.Copyright ©; 2011, Кондратьев А.И.2011Kondratiev A.I.Кондратьев А.И.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/126

Aim – to estimate the clinical and pharmacological effects of ivabradine in complex treatment of patients with acute coronary syndrome anddiabetes mellitus type 2 (DM 2).

Materials and methods. The study included 36 patients with acute coronary insufficiency (unstable angina) and acute left ventricular failure(Killip class I–III) during concomitant type 2 diabetes.

Results. Prescribing ivabradine in treatment of unstable angina pectoris complicated by type 2 diabetes led to decrease in clinical symptoms,heart rate and reduce in number of myocardial ischemia episodes. Patients treated with ivabradine, showed a significant tendency to increase left ventricular ejection fraction (12.3 %). Mo adverse reactions were recorded, including hypotensive complications.

Conclusion. Ivabradine therapy was characterized by high ischemic and antianginal efficacy, good tolerability, did not lead to the developmentof tolerance and was not accompanied by the appearance of withdrawal syndrome.

acute coronary syndromediabetes mellitus type 2treatmentострый коронарный синдромсахарный диабет 2-го типалечение1. Сторожаков Г.И. Дилатационная кардиомиопатия – связь с воспалением. Журнал Сердечная недостаточность 2008;2:91–7.Сторожаков Г.И. Дилатационная кардиомиопатия – связь с воспалением. Журнал Сердечная недостаточность 2008;2:91–7.2. Терещенко С.Н., Косицына И.В., Голубев А.В. Возможность применения ивабрадина в комплексной терапии острого коронарного синдрома. Кардиология 2008;7:10–13.Терещенко С.Н., Косицына И.В., Голубев А.В. Возможность применения ивабрадина в комплексной терапии острого коронарного синдрома. Кардиология 2008;7:10–13.3. Seccareccia F., Pannozzo F., Dima F. et al; Malattie Cardiovascolari Aterosclerotiche IstitutoSeccareccia F., Pannozzo F., Dima F. et al; Malattie Cardiovascolari Aterosclerotiche IstitutoSuperiore di Sanita Project. Heart rate as a predictor of mortality: the MATISS Project. Am J Public Health 2001;91:1258–63.4. Di Francesco D. I(f) current inhibitors: properties of drug channel interraction. In: Selective and specific I(f) channel inhibition in cardiology. Fox K., ed. London: Science Press, 2004; p. 1–13.Di Francesco D. I(f) current inhibitors: properties of drug channel interraction. In: Selective and specific I(f) channel inhibition in cardiology. Fox K., ed. London: Science Press, 2004; p. 1–13.5. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II-DAVIT-II). Am J Cardiol 1990;66:779–85.The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II-DAVIT-II). Am J Cardiol 1990;66:779–85.6. Шальнова С.А., Деев А.Д., Оганов Р.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология 2005;10:45–50.Шальнова С.А., Деев А.Д., Оганов Р.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология 2005;10:45–50.7. Ерофеева С.Б., Манешина О.А., Белоусов Ю.Б. Место ивабрадина – первого If ингибитора избирательного и специфического действия, в лечении сердечно-сосудистых заболеваний. КачественнаяЕрофеева С.Б., Манешина О.А., Белоусов Ю.Б. Место ивабрадина – первого If ингибитора избирательного и специфического действия, в лечении сердечно-сосудистых заболеваний. Качественнаяклиническая практика 2006;1:10–22.8. Mulder P., Barbie S., Chagraoui A., et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674–9.Mulder P., Barbie S., Chagraoui A., et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674–9.9. Borer J.S., Fox K., Jaillon P., et al.; Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebocontrolled trial. Circulation 2003;107:817–23.Borer J.S., Fox K., Jaillon P., et al.; Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebocontrolled trial. Circulation 2003;107:817–23.10.Monnet X., Colin P., Ghaleh B., et al. Heart rate reduction during exercise-induced myocardial ischemia and stunning. Eur Heart JMonnet X., Colin P., Ghaleh B., et al. Heart rate reduction during exercise-induced myocardial ischemia and stunning. Eur Heart J2004;25:579–86.;25:579–86.11. Дедов И.И., Александров А.А. Диабетическое сердце: Causa Magna. Сердце 2004;3(1):5–8.Дедов И.И., Александров А.А. Диабетическое сердце: Causa Magna. Сердце 2004;3(1):5–8.12. Кремнева Л.В., Шалаев С.В. Гипергликемия у больных острым коронарным синдромом. Атеротромбоз 2009;(1):86–94.Кремнева Л.В., Шалаев С.В. Гипергликемия у больных острым коронарным синдромом. Атеротромбоз 2009;(1):86–94.13. Оганов Р.Г., Мамедов М.Н. Национальные клинические рекомендации Всероссийского научного общества кардиологов.Оганов Р.Г., Мамедов М.Н. Национальные клинические рекомендации Всероссийского научного общества кардиологов.М.: Меди ЭКСПО, 2009.14. Malmberg K., Herlitz J., Hjalmarson A., Ryden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acuteMalmberg K., Herlitz J., Hjalmarson A., Ryden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acutemyocardial infarction. Retrospective data from two large studies. Eur Heart J 1989;10(5):423–8.15. Gundersen T., Syekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6:285–90.Gundersen T., Syekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6:285–90.16. Lowel H., Koenig W., Engel S., et al. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population – based myocardial infarction register follow-up study. Diabetologia 2000;43:218–26.Lowel H., Koenig W., Engel S., et al. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population – based myocardial infarction register follow-up study. Diabetologia 2000;43:218–26.17. Kveiborg B., Hermann T.S., Major-Pedersen A., et al. Metoprolol compared to carvedilol deteriorates insulin-stimulatedKveiborg B., Hermann T.S., Major-Pedersen A., et al. Metoprolol compared to carvedilol deteriorates insulin-stimulatedendothelial function in patients with type 2 diabetes – a randomized study. Cardiovasc Diabetol 2010;9:21.18. Fox K., Ford I., Steg P.G., et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunctionFox K., Ford I., Steg P.G., et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction(BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;10:70–8.